An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis

被引：0
|
作者：
Galazka, A. [1 ]
Nolting, A. [2 ]
Cook, S. [3 ]
Leist, T. [4 ]
Comi, G. [5 ]
Montalban, X. [6 ,7 ]
Hicking, C. [2 ]
Dangond, F. [8 ]
机构：
[1] Merck, Aubonne, Switzerland
[2] Merck KGaA, Darmstadt, Germany
[3] Rutgers State Univ, New Jersey Med Sch, Newark, NJ USA
[4] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[5] Univ Vita Salute San Raffaele, Milan, Italy
[6] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[7] Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain
[8] EMD Serono Inc, Billerica, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1083
引用
收藏
页码：133 / 133
页数：1
相关论文
共 50 条
  • [1] AN ANALYSIS OF MALIGNANCY RISK IN THE CLINICAL DEVELOPMENT PROGRAMME OF CLADRIBINE TABLETS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    Galazka, Andrew
    Nolting, Axel
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Hicking, Christine
    King, John
    Dangond, Fernando
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E17 - E17
  • [2] An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis (RMS)
    Galazka, A.
    Nolting, A.
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 999 - 1000
  • [3] The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
    Hermann, Robert
    Karlsson, Mats O.
    Novakovic, Ana M.
    Terranova, Nadia
    Fluck, Markus
    Munafo, Alain
    CLINICAL PHARMACOKINETICS, 2019, 58 (03) : 283 - 297
  • [4] The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
    Robert Hermann
    Mats O. Karlsson
    Ana M. Novakovic
    Nadia Terranova
    Markus Fluck
    Alain Munafo
    Clinical Pharmacokinetics, 2019, 58 : 283 - 297
  • [5] Cladribine Tablets for Treatment of Patients with Multiple Sclerosis (MS): Integrated Analysis of Safety from the MS Clinical Development Programme
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Sylvester, E.
    Hicking, C.
    Dangond, F.
    King, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 397 - 397
  • [6] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [7] Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development program
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Sylvester, E.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 305 - 306
  • [8] Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2020, 34 : 447 - 447
  • [9] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [10] Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis
    Sorensen, Per Soelberg
    Centonze, Diego
    Giovannoni, Gavin
    Montalban, Xavier
    Selchen, Daniel
    Vermersch, Patrick
    Wiendl, Heinz
    Yamout, Bassem
    Salloukh, Hashem
    Rieckmann, Peter
    NEUROLOGY, 2020, 94 (15)
12345